等待開盤 12-23 09:30:00 美东时间
+0.910
+1.39%
CYTK: 8% | Cytokinetics shares were trading higher after the company announced that the FDA approved MYQORZO, 5 mg, 10 mg, 15 mg, 20 mg tablets for the treatment of adults with symptomatic obstructive hypertrophic
12-22 20:38
WISeKey International Holding Ltd issued a shareholder letter highlighting 2025 as a milestone year in executing its long-term strategy as a technology holding company. Key achievements include the strategic acquisition of IC’ALPS, the launch of a $100 million Quantum Fund, the commercial release of Quantum Shield QS7001™ and QVault™ solutions, and the upcoming listing of WISeSat via a SPAC merger. The company also announced SEALCOIN’s preparatio...
12-22 06:00
Plus: Global M&A activity surged in 2025, with announced deal value climbing 46% year over year to about $4.4 trillion.
12-20 04:45
The PL-16 Viral Blocker has shown over 90% success in protection of cells against virusesRaanana, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd., a pre-clinical-stage biotechnology company developing intranasal
12-19 21:23
Israeli Prime Minister Benjamin Netanyahu on Wednesday said he approved a $35 billion agreement to supply natural gas to Egypt, a deal he said would deepen economic ties despite strained relations bet...
12-19 00:48
Something interesting is happening in the usually quiet world of U.S. Treasury markets. Traditional asset managers who spent years dismissing cryptocurrency are now building products that live entirely on blockchains. The twist? They’re tokenizing the safest asset class in existence: government debt.
12-18 23:27
Afentra ( ($GB:AET) ) just unveiled an update. Afentra plc has completed the di...
12-18 22:52
Spirax Group ( ($GB:SPX) ) just unveiled an announcement. Spirax Group PLC has ...
12-18 22:21
Milestone Underscores Accelerating Institutional Adoption of Blockchain Technology and Aligns with Tharimmune's Canton Coin Treasury Strategy NEW YORK, Dec. 18, 2025 /PRNewswire/ -- Tharimmu...
12-18 21:15
Stifel analyst Jonathan Block maintains ResMed (NYSE:RMD) with a Hold and lowers the price target from $270 to $260.
12-18 21:04